Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

May 30, 2025 1:00 AM EDT

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit

AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial

Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials

Regeneron and Sanofi are assessing the data and will discuss next steps with regulatory authorities

TARRYTOWN, N.Y. and PARIS, May 30, 2025... More

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

May 30, 2025 1:00 AM EDT

Itepekimab met the primary endpoint in one of two COPD phase 3 studies

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and Regeneron are assessing the... More